Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (11)
Type
(
1 selected
)
Type
Guidance (303)
Quality standard (29)
Guidance programme
Guidance programme
Health technology evaluations (6)
Highly specialised technologies guidance (2)
Interventional procedures guidance (10)
Medical technologies guidance (2)
Technology appraisal guidance (283)
Apply filters
Showing 21 to 30 of 303
Type: Guidance
Remove Type: Guidance filter
Guidance and quality standards awaiting development
Title
Type
Balloon cryoablation for Barrett's oesophagus
Interventional procedures guidance
Baloxavir marboxil for Influenza [ID6552]
Technology appraisal guidance
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]
Technology appraisal guidance
Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]
Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]
Technology appraisal guidance
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [TSID12142]
Technology appraisal guidance
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Technology appraisal guidance
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]
Technology appraisal guidance
Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]
Technology appraisal guidance
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]
Technology appraisal guidance
Previous page
1
2
Current page
3
4
5
…
31
Page
3
of
31
Next page
Results per page
10
25
50
All
Back to top